Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.32 |
| ▸ | HTR3B | O95264 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.32 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8467 | 0.97 | — | — | |
| SCHEMBL930605 | 0.97 | — | — | |
| SCHEMBL10578128 | 0.97 | CA2 (0.35) | CA2CHKAHSD17B10CA12CA1 | |
| SCHEMBL12671511 | 0.97 | CA2 (0.35) | CA2CHKAHSD17B10CA12CA1 | |
| SCHEMBL24672240 | 0.94 | HIF1A (0.35) | CA2CHKAHSD17B10CA12CA1 | |
| Hydrochloric Acid SCHEMBL17560377 | 0.94 | CA2 (0.33) | CA2CHKAHSD17B10CA12CA1 | |
| SCHEMBL472206 | 0.94 | HIF1A (0.35) | CA2CHKAHSD17B10CA12CA1 | |
| Hydrochloric Acid SCHEMBL1739117 | 0.94 | — | — | |
| SCHEMBL3881127 | 0.94 | CA2 (0.33) | CA2CHKAHSD17B10CA12CA1 | |
| SCHEMBL16667767 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981953-B1 | Contrast agent precursor and method for preparing the same | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2018-05-29 | — | — | US | disclosed |
| US-9981953-B1 | Contrast agent precursor and method for preparing the same | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2018-05-29 | — | — | US | disclosed |
| US-7928096-B2 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090068248-A1 | POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE (US) | 2009-03-12 | — | — | US | disclosed |
| US-7468435-B2 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | THERAPHARM GMBH (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | THERAPHARM GMBH (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20050148566-A1 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE GOVERNMENT OF THE USA, AS REP. BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068248-A1 | POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME | NOS2, ARG2, NOS1 | CA2 179/4885CHKA 2019/4885HSD17B10 3974/4885 |
| US-20080312430-A1 | Method of Preparing or Synthesizing Polyazamacrocycle Derivatives | POLI, PARP1, DHPS | CA2 4117/4885CHKA 3127/4885HSD17B10 1028/4885 |
| US-20050148566-A1 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | NOS2, ARG2, NOS1 | CA2 179/4885CHKA 2019/4885HSD17B10 3974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.